IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate.
Thuy T Le, Kresten Skak, Kate Schroder, Wayne A Schroder, Glen M Boyle, Carly J Pierce, Andreas Suhrbier
Author Information
Thuy T Le: Inflammation Biology, and Cancer Drug Mechanism Laboratories, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Kresten Skak: Leo Pharma, Copenhagen, Denmark.
Kate Schroder: Inflammasome Laboratory, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, Brisbane, Queensland, Australia.
Wayne A Schroder: Inflammation Biology, and Cancer Drug Mechanism Laboratories, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Glen M Boyle: Inflammation Biology, and Cancer Drug Mechanism Laboratories, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Carly J Pierce: Inflammation Biology, and Cancer Drug Mechanism Laboratories, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Andreas Suhrbier: Inflammation Biology, and Cancer Drug Mechanism Laboratories, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Ingenol mebutate is approved for the topical treatment of actinic keratoses and may ultimately also find utility in treating skin cancers. Here we show that relapse rates of subcutaneous B16 melanoma tumours treated topically with ingenol mebutate were not significantly different in C57BL/6 and Rag1-/- mice, suggesting B and T cells do not play a major role in the anti-cancer efficacy of ingenol mebutate. Relapse rates were, however, significantly increased in MyD88-/- mice and in C57BL/6 mice treated with the anti-IL-1 agent, anakinra. Ingenol mebutate treatment induces a pronounced infiltration of neutrophils, which have been shown to have anti-cancer activity in mice. Herein we provide evidence that IL-1 promotes neutrophil recruitment to the tumour, decreases apoptosis of infiltrating neutrophils and increases neutrophil tumour killing activity. These studies suggest IL-1, via its action on neutrophils, promotes the anti-cancer efficacy of ingenol mebutate, with ingenol mebutate treatment causing both IL-1β induction and IL-1α released from keratinocytes.
References
Immunity. 2012 Mar 23;36(3):388-400
[PMID: 22444631]
Immunity. 2013 Dec 12;39(6):1003-18
[PMID: 24332029]
